FEDERAL RESERVE SYSTEM

Barclays PLC, London, England;

Barclays Bank PLC, London, England; Proposal to Underwrite and Deal in Certain Securities to a Limited Extent

Barclays PLC, London, England, and Barclays Bank PLC, London, England (collectively "Applicant"), have applied, pursuant to section 4(c)(8) of the Bank Holding Company Act (12 U.S.C. 1843(c)(8) (the "BHC Act"), § 225.23(a)(3) of the Board's Regulation Y (12 CFR 225.23(a)(3)), for prior approval to engage through Barclays de Zoete Wedd Securities, Inc., New York, ("Company"), in underwriting and dealing, to a limited extent, in all types of equity securities, except securities issued by open-end investment companies, on a world-wide basis.

Company is currently authorized to engage (i) In underwriting and dealing in government obligations and money market instruments, pursuant to § 225.25(b)(16) of the Board's Regulation Y (12 CFR 225.25(b)(16)); (ii) in underwriting and dealing in debt securities, pursuant to Board order, *Canadian Imperial Bank of Commerce, The Royal Bank of Canada, Barclays PLC, and Barclays Bank PLC*, 76 Federal Reserve Bulletin 158 (1990) ("*Canadian Imperial*"); (iii) in providing investment or financial advice, pursuant to § 225.25(b)(4) of the Board's Regulation Y (12 CFR 225.25(b)(4)); and (iv) in acting as a futures commission merchant, pursuant to §§ 225.25(b)(18) and (b)(19) of the Board's Regulation Y (12 CFR 225.25(b)(18) and (b)(19)).

Section 4(c)(8) of the BHC Act provides that a bank holding company may, with prior Board approval, engage directly or indirectly in any activities "which the Board after due notice and opportunity for hearing has determined (by order or regulation) to be so closely related to banking or managing or controlling banks as to be a proper incident thereto."

A particular activity may be found to meet the "closely related to banking" test if it is demonstrated that banks have generally provided the proposed activity; that banks generally provide services that are operationally or functionally so similar to the proposed activity so as to equip them particularly well to provide the proposed activity; or that banks generally provide services that are so integrally related to the proposed activity as to acquire their provision in a specialized form. *National Courier Ass'n* v. *Board of Governors*, 516 F. 2d 1229, 1337 (DC Cir. 1975). In addition, the Board may consider any other basis that may demonstrate that the activity has a reasonable or close relationship to banking or managing or controlling banks. Board Statement Regarding Regulation Y, 49 Federal Register 806 (1984).

In determining whether an activity meets the second, or proper incident to banking, test of section 4(c)(8), the Board must consider whether the performance of the activity by an affiliate of a holding company "can reasonably be expected to produce benefits to the public, such as greater convenience, increased competition, or gains in efficiency that outweigh possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of interests, or unsound banking practices."

Applicant has applied to underwrite and deal in equity securities in accordance with the Board's prior orders approving those activities for a number of bank holding companies.

Canadian Imperial

Applicant contends that approval of the application would not be barred by section 20 of the Glass-Steagall Act (12 U.S.C. 377). Section 20 of the Glass-Steagall Act prohibits the affiliation of a member bank with a firm that is "engaged principally" in the "underwriting, public sale or distribution" of securities. With regard to the proposed equity securities underwriting and dealing activities, Applicant states that, consistent with section 20, it would not be "engaged principally" in such activities on the basis of the restriction on the amount of the proposed activity relative to the total business conducted by the underwriting subsidiary previously approved by the Board. See Board's Order dated September 21, 1989, 75 Federal Reserve Bulletin 751 (1989).

In publishing the proposal for comment, the Board does not take any position on issues raised by the proposal under the BHC Act. Notice of the proposal is published solely in order to seek the views of interested persons on the issues presented by the application and does not represent a determination by the Board that the proposal meets or is likely to meet the standards of the BHC Act.

Any views or requests for a hearing should be submitted in writing and received by William W. Wiles, Secretary, Board of Governors of the Federal Reserve System, Washington, DC 20551, not later than December 21, 1990. Any request for a hearing must, as required by § 262.3(e) of the Board's Rules of Procedure (12 CFR 262.3(E)), be accompanied by a statement of why a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented in a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal.

This application may be inspected at the offices of the Board of Governors or the Federal Reserve Bank of New York.

Board of Governors of the Federal Reserve System, November 21, 1990.

Jennifer J. Johnson,

Associate Secretary of the Board.

[FR Doc. 90-27895 Filed 11-27-90; 8:45 am]

BILLING CODE 6210-01-M

Sun Financial Corp.; Correction

This notice corrects a previous Federal Register notice (FR Doc. 90-26672) published at page 47392 of the issue for Tuesday, November 13, 1990.

Under the Federal Reserve Bank of St. Louis, the entry for Sun Financial Corporation, Earth City, Missouri, should be amended to add:

1. *Sun Financial Corp.*, Earth City, Missouri, to engage through its subsidiary bank, Farmers State Bank of Ellington, Ellington, Missouri, in acting as principal, agent, or broker for insurance (including home mortgage redemption insurance) that is (a) Directly related to an extension of credit by the bank holding company or any of its subsidiaries; and (b) limited to ensuring the repayment of the outstanding balance due on the extension of credit in the event of the death, disability, or involuntary unemployment of the debtor. See § 225.25(b)(8)(i) of the Board's Regulation Y (12 CFR 225.25(b)(8)(i)).

Comments on this application must be received by December 17, 1990.

Board of Governors of the Federal Reserve System, November 21, 1990.

Jennifer J. Johnson,

Associate Secretary of the Board.

[FR Doc. 90-27896 Filed 11-27-90; 8:45 am]

BILLING CODE 6210-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Advisory Committees; Renewals

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) announces the

renewal of certain FDA advisory committees by the Secretary of Health and Human Services. This notice is issued under the Federal Advisory Committee Act of October 6, 1972 (Pub. L. 92–463 (5 U.S.C. app. 2)).

DATES: Authority for these committees will expire on the date indicated below unless the Secretary formally determines that renewal is in the public interest.

Name of committee	Date of expiration
Allergenic Products	July 9, 1992.
Cardiovascular and Renal Drugs	Aug. 27, 1992.
Endocrinologic and Metabolic Drugs.	Aug. 27, 1992.
Oncologic Drugs	Sept. 1, 1992.
Anti-Infective Drugs	Oct. 7, 1992.
Dermatologic Drugs	Oct. 7, 1992.
Biological Response Modifiers	Oct. 28, 1992.

FOR FURTHER INFORMATION CONTACT: Richard L. Schmidt, Committee Management Office (HFA–306), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–2765.

Dated: November 20, 1990.

Alan L. Hoeting,

Acting Associate Commissioner for Regulatory Affairs.

[FR Doc. 90–27855 Filed 11–27–90; 8:45 am]

BILLING CODE 4160–01–M

[Docket No. 90F–0344]

Ciba-Geigy Corp.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Ciba-Geigy Corp. has filed a petition proposing that the food additive regulations be amended to provide for the safe use of polymaleic acid and its sodium salt to control mineral scale during production of beet and cane sugar juice and liquor.

FOR FURTHER INFORMATION CONTACT: Vincent Zenger, Center for Food Safety and Applied Nutrition (HFF–334), Food and Drug Administration, 200 C Street SW., Washington, DC 20204, 202–472–5690.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that Ciba-Geigy Corp., Seven Skyline Dr., Hawthorne, NY 10532–2188, has filed a petition (FAP OA4226), proposing that § 173.45 *Polymaleic acid and its sodium salt* (21 CFR 173.45) be amended to provide for the safe use of polymaleic acid (CAS Reg. No. 26099–09–2) and its sodium salt (CAS Reg. No. 70247–90–4) to control mineral scale during production of beet and cane sugar juice and liquor at higher levels than the maximum currently permitted under the regulation.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: November 19, 1990.

Fred R. Shank,

Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 90–27954 Filed 11–27–90; 8:45 am]

BILLING CODE 4160–01–M

[Docket No. 90P–0352]

Eggnog Deviating From Identity Standard; Temporary Permit for Market Testing

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a temporary permit has been issued to Cumberland Farms, Inc., to market test a product designated as "light eggnog" that deviates from the U.S. standard of identity for eggnog (21 CFR 131.170). The purpose of the temporary permit is to allow the applicant to measure consumer acceptance of the product.

DATES: This permit is effective for 15 months, beginning on the date the food is introduced or caused to be introduced into interstate commerce, but not later than February 26, 1991.

FOR FURTHER INFORMATION CONTACT: Frederick E. Boland, Center for Food Safety and Applied Nutrition (HFF–414), Food and Drug Administration, 200 C Street SW., Washington, DC 20204, 202–485–0117.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 130.17 concerning temporary permits to facilitate market testing of foods deviating from the requirements of the standards of identity promulgated under section 401 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 341), FDA is giving notice that a temporary permit has been issued to Cumberland Farms, Inc., 777 Dedham St., Canton, MA 02021, and Route 130, Cumberland Blvd., Burlington, NJ 08016.

The permit covers limited interstate marketing tests of a product that deviates from the U.S. standard of identity for eggnog in 21 CFR 131.170 in that: (1) The fat content of the product is reduced from 6 percent to 1 percent, and (2) sufficient vitamin A palmitate is added in a suitable carrier to ensure that a 4-fluid ounce (118.5-milliliter) serving of the product contains 8 percent of the U.S. Recommended Daily Allowance for vitamin A. The product meets all requirements of the standard with the exception of these deviations. The purpose of the variation is to offer the consumer a product that is nutritionally equivalent to eggnog but contains fewer calories and less fat.

For the purpose of this permit, the name of the product is "light eggnog." The principal display panel of the label must include the statements "reduced calories" and "reduced fat" following the name. In addition, the label must bear the comparative statements "⅓ less calories" and "75% less fat than regular eggnog."

The product complies with the reduced calorie labeling requirements in 21 CFR 105.66(d). In accordance with FDA's current views, reduced fat food labeling is acceptable because there is at least a 50-percent reduction in the fat content of the product. The information panel of the label will bear nutrition labeling in accordance with 21 CFR 101.9.

This permit provides for the temporary marketing of 180,000 quarts (170,334 liters) of the test product. The product will be manufactured at Cumberland Farms, Inc., 777 Dedham St., Canton, MA 02021, and Route 130, Cumberland Blvd., Burlington, NJ 08016, and distributed in Connecticut, Delaware, Maine, Maryland, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont.

Each of the ingredients used in the food must be declared on the label as required by the applicable sections of 21 CFR part 101. This permit is effective for 15 months, beginning on the date the food is introduced or caused to be introduced into interstate commerce, but not later than February 26, 1991.

Dated: November 15, 1990.

Fred R. Shank,

Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 90–27955 Filed 11–27–90; 8:45 am]

BILLING CODE 4160–01–M

[Docket No. 90P-0365]

Eggnog Deviating From Identity Standard; Temporary Permit for Market Testing

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMMARY: The Food and Drug Administration (FDA) is announcing that a temporary permit has been issued to Foremost Dairies-Hawaii, House Foods Hawaii Corp., to market test a product designated as "light eggnog" that deviates from the U.S. standard of identity for eggnog (21 CFR 131.170). The purpose of the temporary permit is to allow the applicant to measure consumer acceptance of the product.

DATES: This permit is effective for 15 months, beginning on the date the food is introduced or caused to be introduced into interstate commerce, but not later than February 26, 1991.

FOR FURTHER INFORMATION CONTACT: Howard A. Anderson, Center for Food Safety and Applied Nutrition (HFF-414), Food and Drug Administration, 200 C Street SW., Washington, DC 20204, 202-485-0349.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 130.17 concerning temporary permits to facilitate market testing of foods deviating from the requirements of the standards of identity promulgated under section 401 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 341), FDA is giving notice that a temporary permit has been issued to Foremost Dairies-Hawaii, House Foods Hawaii Corp., 2277 Kamehameha Highway, Honolulu, HI 96819.

The permit covers limited interstate marketing tests of a product that deviates from the U.S. standard of identity for eggnog in 21 CFR 131.170 in that: (1) The fat content of the product is reduced from 6 percent to 1 percent, and (2) sufficient vitamin A palmitate is added in a suitable carrier to ensure that a 4-fluid-ounce (118.5-milliliter) serving of the product contains 8 percent of the U.S. Recommended Daily Allowance for vitamin A. The product meets all requirements of the standard with the exception of these deviations. The purpose of the variation is to offer the consumer a product that is nutritionally equivalent to eggnog but contains fewer calories and less fat.

For the purpose of this permit, the name of the product is "light eggnog." The principal display panel of the label must include the statements "reduced calories" and "reduced fat" following the name. In addition, the label must bear the comparative statements "⅓ less calories" and "75% less fat than regular eggnog".

The product complies with the reduced calorie labeling requirements in 21 CFR 105.66(d). In accordance with FDA's current views, reduced fat food labeling is acceptable because there is at least a 50-percent reduction in the fat content of the product. The information panel of the label will bear nutrition labeling in accordance with 21 CFR 101.9.

This permit provides for the temporary marketing of 15,000 quarts (14,194 liters) of the test product. The test product is to be manufactured at Foremost Dairies-Hawaii, 2277 Kamehameha Highway, Honolulu, HI 96819, nnd distributed in Hawaii.

Each of the ingredients used in the food must be declared on the label as required by the applicable sections of 21 CFR part 101. This permit is effective for 15 months, beginning on the date the food is introduced or caused to be introduced into interstate commerce, but not later than February 26, 1991.

Dated: November 16, 1990.

Fred R. Shank,

Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 90-27956 Filed 11-27-90; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 90N-0401]

Interpharm, Inc.; Withdrawal of Approval of Abbreviated New Drug Applications for Clonidine Hydrochloride Tablets

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of three abbreviated new drug applications (ANDA's) for Clonidine Hdrochloride Tablets held by Interpharm, Inc., Three Fairfield Ave., Plainfield, NY 11803 (Interpharm). Interpharm has requested that FDA withdraw approval of these ANDA's because the applications contain discrepancies between the product tested for bioequivalence and the information submitted in the applications.

EFFECTIVE DATE: November 28, 1990.

FOR FURTHER INFORMATION CONTACT: Margaret F. Sharkey, Center for Drug Evaluation and Research (HFD-366), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-295-8041.

SUPPLEMENTARY INFORMATION: Recently, FDA became aware of the difference between the product tested for bioequivalence and the statements submitted in support of the approval of the following ANDA's held by Interpharm:

1. ANDA 71-252; for clonidine hydrochloride tablets, 0.1 milligram (mg).

2. ANDA 71-253; for clonidine hydrochloride tablets, 0.2 (mg).

3. ANDA 71-254; for clonidine hydrochloride tablets, 0.3 (mg).

FDA asked Interpharm to remove the products from the market and to request that FDA withdraw approval of the applications. Interpharm complied with the request. The firm recalled the products to the retail level and, on July 3, 1990, Interpharm requested that approval of the three ANDA's be withdrawn.

Therefore, under section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)) and under authority delegated to the Director of the Center for Drug Evaluation and Research (21 CFR 5.82), approval of abbreviated new drug applications 71-252, 71-253, and 71-254, and all amendments and supplements thereto, is hereby withdrawn, effective November 28, 1990.

Dated: November 19, 1990.

Carl C. Peck,

Director, Center for Drug Evaluation and Research.

[FR Doc. 90-27885 Filed 11-27-90; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 90N-0378]

Martec Pharmaceutical, Inc., et al.; Withdrawal of Approval of Abbreviated New Drug Applications

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of 84 abbreviated new drug applications (ANDA's). The holders of the ANDA's notified the agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.

EFFECTIVE DATE: December 28, 1990.

FOR FURTHER INFORMATION CONTACT: Lola E. Batson, Center for Drug Evaluation and Research (HFD-360), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-295-8038.